Download App

Log in to access Online Inquiry
Company Overview More
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. It’s pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer’s disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer’s. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
CEO: Davis J.D., Stephen R.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

ACAD ACADIA Pharmaceuticals

16.790-0.320-1.87%
Close 05/23 18:24 ET
17.200+0.41+2.44%
Post Mkt Price 05/23 16:05 ET
High
17.430
Open
17.330
Turnover
19.65M
Low
16.480
Pre Close
17.110
Volume
1.17M
Market Cap
2.71B
P/E(TTM)
Loss
52wk High
28.055
Shares
161.43M
P/E(Static)
Loss
52wk Low
15.160
Float Cap
2.00B
Bid/Ask %
0.00%
Historical High
58.720
Shs Float
119.11M
Volume Ratio
0.85
Historical Low
0.650
Dividend TTM
--
Div Yield TTM
1000
P/B
6.09
Dividend LFY
--
Div Yield LFY
5955.93%
Turnover Ratio
0.98%
Amplitude
5.55%
Avg Price
16.777
Lot Size
1
Float Cap
2.00B
Bid/Ask %
0.00%
Historical High
58.720
Shs Float
119.11M
Volume Ratio
0.85
Historical Low
0.650
Dividend TTM
--
P/B
6.09
Dividend LFY
--
Turnover Ratio
0.98%
Amplitude
5.55%
Avg Price
16.777
Lot Size
1
Price Forecast

No Data

News

Comment